

Appl. No. 09/926,286

Amdt. Dated January 31, 2005

Reply to Final Office Action of August 31, 2004

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of claims:

1. (Currently amended) A method for ~~reducing~~ inhibiting invasiveness and/or migration of malignant cells in a patient in need of ~~a reduction~~ an inhibition in the invasiveness and/or migration of malignant cells comprising

administering to the patient an active ingredient consisting essentially of at least one alpha lipoic acid or at least one physiologically equivalent derivative thereof in an invasiveness and/or migration of malignant cells ~~reducing~~ inhibiting effective amount, and a pharmaceutically acceptable carrier therefor.

2. (Previously presented) The method of claim 1 wherein said at least one physiologically equivalent derivative of alpha lipoic acid is a salt, ester or inclusion complex.

3. (Previously presented) The method of claim 2 wherein said salt is a pharmaceutically acceptable salt.

4. (Previously presented) The method of claim 1 wherein said at least one alpha lipoic acid or physiologically equivalent derivative thereof is administered orally, intravenously or subcutaneously.

5. (Previously presented) The method of claim 1 wherein said at least one alpha lipoic acid or physiologically equivalent derivative thereof is administered topically, rectally or by inhalation.

6. (Previously presented) The method of claim 1, wherein said active ingredient is administered in a daily dose of about 0.5 to about 5g.

7. (Currently amended) The method of claim 1, wherein said at least one alpha lipoic acid or physiologically equivalent derivative thereof ~~reduces~~ inhibits invasiveness of malignant cells.

8. (Currently amended) The method of claim 1, wherein said at least one alpha lipoic acid or physiologically equivalent derivative thereof ~~reduces~~ inhibits migration of malignant cells.

9. (Previously presented) A method for promoting adhesion of malignant cells in a patient in need of a promotion in the adhesion of malignant cells comprising

administering to the patient a composition comprising an active ingredient consisting essentially of at least one alpha lipoic acid or at least one physiologically equivalent derivative thereof in an adhesion of malignant cells promoting effective amount, and a pharmaceutically acceptable carrier therefor.

10. (Previously presented) A method according to claim 10, wherein said adhesion is adhesion to a basal membrane.

11. (Currently amended) A method for ~~reducing~~ inhibiting metastasis in a patient in need of a ~~reduction~~ an inhibition of metastasis comprising

administering to the patient a composition comprising an active ingredient consisting essentially of at least one alpha lipoic acid or at least one physiologically equivalent derivative thereof in a metastasis ~~reducing~~ inhibiting effective amount, and a pharmaceutically acceptable carrier therefor.

12. (Previously presented) The method of claim 11 wherein said at least one physiologically equivalent derivative of alpha lipoic acid is a salt, ester or inclusion complex.

13. (Previously presented) The method of claim 12 wherein said salt is a pharmaceutically acceptable salt.

14. (Previously presented) The method of claim 11 wherein said composition is administered orally, intravenously or subcutaneously.

15. (Previously presented) The method of claim 11 wherein said composition is administered topically, rectally or by inhalation.

16. (Previously presented) The method of claim 11, wherein said composition is administered in a daily dose of about 0.5 to about 5g.

Appl. No. 09/926,286

Amdt. Dated January 31, 2005

Reply to Final Office Action of August 31, 2004

17. (Previously presented) The method of claim 11, wherein metastasis is prevented.